Sign up
Pharma Capital

VolitionRx chief hails "wonderful" progress accomplished in 2016

Cameron Reynolds, chief executive at blood-based diagnostic tests company VolitionRx (NYSEMKT:VNRX), discusses the group's full-year results with Proactive Investors.

 

View full VNRX profile

VolitionRx Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.